Skip to main content

Table 4 Benefits total by score sociodemographic and clinical variables

From: The relationship between self-efficacy and treatment satisfaction among patients with anticoagulant therapy: a cross-sectional study from a developing country

Variable

Frequency % N(300)

Median (Q1–Q3)

Mean ± SD

Mean rank

P value

Age category (years)

< 0.001 b

  < 30

31 (10.3)

15.00(14.00–15.00)

14.55 ± 0.89

255.40

 30–60 

163 (54.3)

12.00(11.00–14.00)

12.08 ± 1.97

159.84

  > 60

106 (35.3)

11.00(9.00–12.00)

10.69 ± 1.93

105.45

Gender

0.015 a

 Male 

115 (38.3)

12.00(10.00–12.00)

11.47 ± 1.98

133.34

 Female 

185 (61.7)

12.00(11.00–14.00)

12.07 ± 2.26

159.92

BMIa 

0.003b

 Normal 

65 (21.7)

12.00(11.00–15.00)

12.63 ± 2.08

178.75

 Overweight 

136 (45.3)

12.00(10.00–13.00)

11.57 ± 2.30

139.13

 Obese 

93 (31.0)

12.00(10.00–13.00)

11.58 ± 1.94

137.90

Education

< 0.001 b

 Illiterate

20 (6.7)

9.50(9.00–11.00)

10.05 ± 1.57

75.45

 Elementary

43 (14.3)

11.00(9.00–12.00)

10.76 ± 1.76

101.92

 Primary

52 (17.3)

12.00(10.00–13.00)

11.73 ± 2.15

145.35

 Secondary

54 (18.0)

12.00(11.00–14.00)

12.19 ± 2.13

159.62

 University

124 (41.3)

12.00(11.00–15.00)

12.38 ± 2.15

166.65

Income (month)

0.641 b

 Less than 2000 NIS

23 (7.7)

12.00(11.00–15.00)

12.17 ± 2.61

160.98

 2000–5000 NIS

160(53.3)

12.00(11.00–14.00)

11.82 ± 2.20

145.83

 More than 5000 NIS

108(36.0)

12.00(10.00–13.00)

11.75 ± 2.09

143.06

locality

0.258 b

 Camp

36 (12.0)

12.00(11.00–14.75)

12.25 ± 2.08

161.86

 Rural

85(28.3)

12.00(11.00–15.00)

12.02 ± 2.30

153.71

 Urban

172(57.3)

12.00(10.00–13.00)

11.66 ± 2.14

140.58

Marital status

0.003 b

 Married

229(76.3)

12.00(11.00–14.00)

12.01 ± 2.14

127.51

 Unmarried (single, divorced, widowed)

67(22.3)

11.00(10.00–13.00)

11.37 ± 2.14

154.64

Employment status

0.188 a

 Employed

194(64.7)

12.00(10.00–13.25)

12.10 ± 1.80

156.46

 Unemployed

100(33.3)

12.00(11.00–14.00)

11.73 ± 2.32

142.88

Chronic co-morbid disease

0.018b

 No co-morbid disease

42 (14.0)

14.00(12.00–15.00)

12.14 ± 1.96

216.07

 One disease

44(14.7)

12.00(10.00–14.00)

11.99 ± 2.10

152.50

 Two diseases

63(21.0)

12.00(10.00–14.00)

12.05 ± 2.06

154.00

 Three diseases or more

146(48.7)

11.00(10.00–12.00)

11.20 ± 2.05

123.50

Indications for anticoagulant

< 0.001 b

 Atrial fibrillation

63 (21.0)

11.00 (9.00–12.00)

10.84 ± 1.90

112.70

 

 Deep vein thrombosis or Pulmonary embolism

29 (9.7)

12.00 (10.50–15.00)

12.31 ± 2.58

167.93

 

 Prophylaxis c

72 (24.0)

13.00 (12.00–15.00)

13.11 ± 1.87

203.99

 Other indications

136 (45.3)

11.00 (10.00–12.75)

11.53 ± 2.03

135.98

Chronic medications

< 0.001 a

  ≤4

176(58.7)

12.00(11.00–15.00)

12.25 ± 2.23

167.30

  > 4

124(41.3)

11.00(10.00–12.00)

11.26 ± 1.96

126.65

Anticoagulant drug

< 0.001 a

 UHF

87(29)

11.00(10.00–12.00)

11.04 ± 1.74

113.63

 Vit-K dependent

134(44.7)

11.50(10.00–13.00)

11.52 ± 2.22

135.54

 NOACs

75(25)

13.00(12.00–15.00)

13.07 ± 1.89

198.53

  1. a The statistical significance of the differences was calculated using the Mann-Whitney U test
  2. b The statistical significance of the differences was calculated using the Kruskal-Wallis test
  3. Bold P-value indicates significant differences.c Patients that received prophylactic doses of unfractionated heparin during hospital admission
  4. NIS: New Israeli Shekel (0.29 US Dollar)
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us